Abstract | BACKGROUND: METHODS: We searched electronic databases including MEDLINE, EMBASE and CENTRAL for randomized controlled trials comparing recombinant factor VIIa with placebo in any patient population except those with hemophilia up to January 2010. Eligible articles were assessed for inclusion, data were extracted, and study quality was evaluated. Outcomes included mortality, blood loss, requirements for red blood cell transfusion, number of patients transfused and thromboembolic events. RESULTS: We identified 26 trials: 14 on off-label prophylactic use of recombinant factor VIIa (n = 1137) and 12 on off-label therapeutic use (n = 2538). In the studies on prophylactic use, we found no significant difference in mortality or thromboembolic events between the treatment and placebo groups. We found modest benefits favouring recombinant factor VIIa in blood loss (weighted mean difference -276 mL, 95% confidence interval [CI] -411 to -141 mL), red blood cell transfusion (weighted mean difference -281 mL, 95% CI -433 to -129 mL) and number of patients transfused (relative risk 0.71, 95% CI 0.50 to 0.99). In the therapeutic trials, we found a nonsignificant decrease in mortality and a nonsignificant increase in thromboembolic events but no difference in control of bleeding or red blood cell transfusion. INTERPRETATION: Clinically significant benefits of recombinant factor VIIa as a general hemostatic agent in patients without hemophilia remain unproven. Given its potential risks, such use cannot be recommended, and in most cases, it should be restricted to clinical trials.
|
Authors | Yulia Lin, Simon Stanworth, Janet Birchall, Carolyn Doree, Christopher Hyde |
Journal | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
(CMAJ)
Vol. 183
Issue 1
Pg. E9-19
(Jan 11 2011)
ISSN: 1488-2329 [Electronic] Canada |
PMID | 21078742
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Recombinant Proteins
- recombinant FVIIa
- Factor VIIa
|
Topics |
- Factor VIIa
(therapeutic use)
- Hemophilia A
- Hemorrhage
(prevention & control)
- Humans
- Off-Label Use
- Recombinant Proteins
(therapeutic use)
- Risk Assessment
|